Literature DB >> 15205913

[Mesotheliomas with leucocytic infiltration].

P Dorfmüller1, M Krismann, K-M Müller.   

Abstract

Malignant mesotheliomas are rare tumors which can affect pleura, peritoneum, pericardium, or tunica vaginalis testis. Histomorphologically, predominant epitheloid, sarcomatoid and biphasic types can be distinguished. In some cases, leucocytic infiltrations can be observed adjacent to the tumor. Here, mesotheliomas presenting inflammatory reactions to tumor growth have to be differentiated from occasional cases with parasynchronic development of neoplastic lymphatic diseases. Moreover, so called lymphohistiocytoid mesotheliomas, a sporadically observed variant of malignant mesotheliomas, have been reported to imitate inflammatory patterns. These different forms of malignant mesotheliomas are difficult to distinguish and may lead to diagnostic misinterpretations and consequently therapeutic mismanagement. The purpose of this study was to differentiate morphological and immunohistochemical characteristics of the above mentioned diagnoses. We therefore studied two rare cases, a mesothelioma with parallel lymphoma and a lymphohistiocytoid mesothelioma, and compared them to a third more common case of mesothelioma with inflammatory tissue-reaction.

Entities:  

Mesh:

Year:  2004        PMID: 15205913     DOI: 10.1007/s00292-004-0705-6

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  17 in total

1.  Synchronous and metachronous primary gastric lymphoma and adenocarcinoma: a clinicopathologic study of 12 patients.

Authors:  N P Zauber; E L Berman
Journal:  Cancer       Date:  1998-01-01       Impact factor: 6.860

Review 2.  [Malignant mesothelioma of the pleura following radiotherapy of Hodgkin disease].

Authors:  L Falchero; B Coiffier; B Guibert; P J Souquet; S Isaac Pinet; V Trillet-Lenoir
Journal:  Bull Cancer       Date:  1996-11       Impact factor: 1.276

3.  Pleural mesothelioma with non-Hodgkin's lymphoma.

Authors:  P Hughes; C R McGavin
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

4.  Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor.

Authors:  A Marrogi; H I Pass; M Khan; L J Metheny-Barlow; C C Harris; B I Gerwin
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

5.  Primary pulmonary collision tumor including squamous cell carcinoma and T-cell lymphoma.

Authors:  O Kawashima; S Sakata; M Kamiyoshihara; A Maeshima; S Ishikawa; Y Morishita
Journal:  Lung Cancer       Date:  1999-01       Impact factor: 5.705

Review 6.  Pleural mesothelioma associated with non-Hodgkin's lymphoma.

Authors:  M Tondini; G Rocco; M Travaglini; G Rossi; A Buscemi; L de Fazio
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

Review 7.  Role of C-X-C chemokines as regulators of angiogenesis in lung cancer.

Authors:  R M Strieter; P J Polverini; D A Arenberg; A Walz; G Opdenakker; J Van Damme; S L Kunkel
Journal:  J Leukoc Biol       Date:  1995-05       Impact factor: 4.962

8.  Association of lymphocytic neoplasia and mesothelioma.

Authors:  A P Efremidis; J S Waxman; A P Chahinian
Journal:  Cancer       Date:  1985-03-01       Impact factor: 6.860

9.  Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases.

Authors:  J Jagirdar; T C Lee; J Reibman; L I Gold; C Aston; R Bégin; W N Rom
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

10.  Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma.

Authors:  T Nakano; A P Chahinian; M Shinjo; A Tonomura; M Miyake; N Togawa; K Ninomiya; K Higashino
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more
  1 in total

1.  Primary intrahepatic malignant mesothelioma of epithelioid type.

Authors:  Ines Gütgemann; Jens Standop; Hans-Peter Fischer
Journal:  Virchows Arch       Date:  2006-03-16       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.